On a first-quarter earnings call Thursday, Emergent’s CEO addressed a turbulent month for the Gaithersburg biopharmaceutical company.
Image: https://www.bizjournals.com
Locally Researched by: Carolyn M. Proctor, Washington Business Journal Apr 30, 2021, 6:00am EDT
Source: The companies, Form 990s, SEC filings and regional economic development agencies
Maryland’s biggest VC funding quarter in 20 years brought $560M to startups – Technical.ly Baltimore
Around Baltimore, folks tend to analyze economic trends through three vantage points: the city, the region and the state. No matter which level you’re looking at, data on venture capital shows that the first quarter of 2021 brought an influx of investment for local emerging companies.
Data from the latest MoneyTree report by PwC/CB Insights shows that Maryland companies received a collective $562 million in investment over 24 deals. It was a nearly 68% increase in the number of dollars and a 26% increase in the number of deals from the fourth quarter of 2020, which capped off a big year of investment in the pandemic.
Image: nsightin Health’s team in the South Baltimore office. (Courtesy photo)
A potential vaccine has brought new life to the embattled Gaithersburg biotech.
Image: Novavax CEO Stanley Erck, left, and Gregory Glenn, head of research and development, at Novavax’s office in Gaithersburg. EMAN MOHAMMED
Oxford, UK – Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $110.5 million. All ADSs sold in the offering are being offered by Vaccitech. The ADSs are expected to begin trading on The Nasdaq Global Market on April 30, 2021 under the ticker symbol “VACC.” In addition, Vaccitech has granted the underwriters a 30-day option to purchase up to an additional 975,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2021, subject to satisfaction of customary closing conditions.
Gain Therapeutics CEO Eric Richman joins BioTalk to Discuss His Career, Redefining Drug Discovery, and Ventures in the BioHealth Capital Region and Beyond.
Listen now on Apple https://apple.co/3vB8mS3, Google https://bit.ly/2QI3xrb, Spotify https://spoti.fi/33021mT, and TuneIn https://bit.ly/2S7Yuk4.
This is a complimentary webinar – the optional attendee list is $39. For registration questions, please email Elizabeth Baker at liz.baker@bisnow.com
What You’ll Learn:
– Why immunology companies with groundbreaking vaccine, cell and gene therapy work are thriving in Montgomery County, MD, home to the National Institutes of Health, the FDA, and 38 federal labs
-How the Montgomery County ecosystem supports companies fast tracking to develop and commercialize products
– Where the region stands on a national and international scale as home to a vibrant, growing life sciences sector
– Why top life science tenants are growing and moving to Montgomery County, MD and the DMV
Image: https://www.bisnow.com
André Marshall will draw from his life experience across innovation and workforce development to drive Mason to new heights, he says.
Image: Andre Marshall, is set to become George Mason University’s vice president for research, innovation and economic development on July 1. – George Mason University – Ron Aira
Montgomery County, Maryland, was a leader in biotechnology before COVID-19 hit, ranking among the highest in the nation for the number of life sciences companies, and the pandemic has only fueled the industry’s growth.
That means more high-paying jobs and demand for research and laboratory-suitable real estate.
There are currently 650 companies operating in the bio-health area in Maryland, including biotechnology and medical device manufacturers. The majority are early-stage companies, but many are now transitioning to later-stage and product manufacturing. Some are well established.
Image: https://biobuzz.io
Are you a servant leader of leaders? Can you “GiveFirst” with no expectation of anything in return? Do you believe that collaboration drives innovation? Do you believe that entrepreneurs can change the world? If so read on…
We are seeking a Managing Director (MD) who can ake the helm and lead our Accelerator and investment strategy for Techstars in Baltimore, Maryland . Your focus is to invest in the best founders, companies and support them from ideation to exit. You will actively recruit, select, mentor and guide founders through challenges, critical decisions, strategy, tactics, securing investment, making hard decisions and celebrating their wins. You will be directly supported by a Program Manager (PM) who focuses on program operations and with you, executing the Techstars proven playbook and delivering the best possible experience for Founders.